Challenges in the Development of Novel Cardiovascular Therapies: New Target for Lowering LDL: PCSK-9

Chief Medical Officer of Amgen, Paul Eisenberg, MD, discusses the insights he has learned working on drug development, specifically the cardiovacscular drug that lowers LDL, PCSK-9.

Paul Eisenberg, MD
Senior Vice President, Global Medical and Chief Medical Officer

Related Videos